Although the number of cathepsin B+ cells is similarly increased in individuals who have AD-DS, we find that the activity of the enzyme is significantly lower than in matched individuals who have EOAD consistent with our hypothesis; this indicates that trisomy of Hsa21 impairs enzyme activity during end-stage disease. This evidence concerns the gene CTSB and Alzheimer disease.